Chemotherapy is the primary treatment for non-Hodgkin lymphoma, though people may also receive it with immunotherapy. Chemotherapy remains the first-line treatment for non-Hodgkin lymphoma (NHL), a ...
This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During the first week of the study, patients received two infusions of rituximab 375 mg/m 2 administered 4 days ...
Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies ...
Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions. Dr. Andre Henri Goy of John Theurer Cancer ...
Results from a clinical trial conducted by researchers at the National Institutes of Health (NIH) show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a ...
Primary thyroid lymphoma (PTL) is an uncommon thyroid malignancy, representing approximately 1–5% of thyroid cancers and 2.5–7% of extranodal lymphomas. Predominantly of B‐cell origin, PTL most ...
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate. The potential Food and Drug ...
On Friday, Incyte Corporation (NASDAQ:INCY) released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to ...
Please provide your email address to receive an email when new articles are posted on . The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results